Clinical Trial Update: ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM) [Phase 4]

View source ↗

Summary

A U.S. pragmatic Phase 4 study (STREAM) is evaluating real-world safety and effectiveness of intrathecal onasemnogene abeparvovec-brve (OAV101B) for Spinal Musc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• onasemnogene abeparvovec-brve (onasemnogene abeparvovec)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Spinal Muscular Atrophy | Phase 4 | Status: NOT_YET_RECRUITING